Researchers asked large commercial labs in the U.S. to report the type and volume of Lyme disease testing conducted in 2008, along with the percent of positive tests.
Seven labs performed about 3.4 million Lyme disease tests at an estimated cost of $492 million. Of those tests, an estimated frequency of infection ranged between 10 percent and 18.5 percent.
“These results highlight the importance of considering clinical and exposure history when interpreting laboratory results for diagnostic and surveillance purposes,” the study authors concluded.
“Before testing a patient for Lyme disease, it is important to consider the likelihood that a patient is infected. If you decide there is a reasonable chance that your patient has Lyme disease, serologic testing may be helpful,” lead author Alison Hinckley, PhD, from the CDC’s Division of Vector-Borne Diseases, told Medscape Medical News.
More Articles on Infection Control:
Study: Multi-Hospital Collaboration Could Significantly Reduce Spread of C. diff
Patient Safety Tooklit: Project RED’s New Toolkit Chapter
CDC Investments in CLABSI Prevention Produce Substantial Benefits
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
